Hsbc Holdings PLC lessened its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 12.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 851,973 shares of the medical research company's stock after selling 126,447 shares during the period. Hsbc Holdings PLC owned about 0.30% of Agilent Technologies worth $99,565,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in A. Valeo Financial Advisors LLC lifted its holdings in Agilent Technologies by 3.0% during the 1st quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company's stock valued at $403,000 after buying an additional 102 shares in the last quarter. Cary Street Partners Financial LLC lifted its holdings in Agilent Technologies by 2.9% during the 1st quarter. Cary Street Partners Financial LLC now owns 3,688 shares of the medical research company's stock valued at $431,000 after buying an additional 103 shares in the last quarter. Western Pacific Wealth Management LP lifted its holdings in Agilent Technologies by 15.2% during the 1st quarter. Western Pacific Wealth Management LP now owns 873 shares of the medical research company's stock valued at $102,000 after buying an additional 115 shares in the last quarter. Bartlett & CO. Wealth Management LLC lifted its holdings in Agilent Technologies by 5.1% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,406 shares of the medical research company's stock valued at $281,000 after buying an additional 116 shares in the last quarter. Finally, Brighton Jones LLC lifted its holdings in Agilent Technologies by 2.6% during the 1st quarter. Brighton Jones LLC now owns 4,784 shares of the medical research company's stock valued at $560,000 after buying an additional 121 shares in the last quarter. Institutional investors own 87.41% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on A shares. Wall Street Zen upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Robert W. Baird cut their target price on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research report on Thursday, May 22nd. Leerink Partners raised their target price on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a research report on Friday, May 30th. UBS Group cut their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research report on Thursday, May 29th. Finally, Evercore ISI raised their target price on shares of Agilent Technologies from $125.00 to $130.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $138.83.
Get Our Latest Report on A
Insiders Place Their Bets
In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.26% of the company's stock.
Agilent Technologies Stock Down 0.7%
Shares of Agilent Technologies stock traded down $0.82 on Tuesday, reaching $118.33. The stock had a trading volume of 318,570 shares, compared to its average volume of 1,932,785. The company has a 50 day moving average price of $117.88 and a 200 day moving average price of $116.87. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $153.84. The stock has a market capitalization of $33.61 billion, a P/E ratio of 29.19, a P/E/G ratio of 3.69 and a beta of 1.22.
Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.26 by $0.05. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The firm had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.63 billion. During the same quarter in the previous year, the firm earned $1.22 EPS. The company's quarterly revenue was up 6.0% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. As a group, equities research analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current year.
About Agilent Technologies
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
